Morgan Stanley initiated coverage on Heartflow with a new price target
$HTFL
Medical/Dental Instruments
Health Care
Morgan Stanley initiated coverage of Heartflow with a rating of Equal-Weight and set a new price target of $35.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/4/2026 | Outperform | William Blair | |
| 1/28/2026 | $38.00 | Overweight | Wells Fargo |
| 9/2/2025 | $36.00 | Overweight | Analyst |
| 9/2/2025 | $38.00 | Overweight | Piper Sandler |
| 9/2/2025 | $35.00 | Buy | Stifel |
| 9/2/2025 | $35.00 | Buy | Canaccord Genuity |
| 9/2/2025 | $35.00 | Equal-Weight | Morgan Stanley |
SCHEDULE 13G/A - Heartflow, Inc. (0001464521) (Subject)
10-Q - Heartflow, Inc. (0001464521) (Filer)
8-K - Heartflow, Inc. (0001464521) (Filer)
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt
VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming
William Blair initiated coverage of Heartflow with a rating of Outperform
Wells Fargo initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00
Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live an
MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Total revenue of $49.1 million, a 40% increase year-over-yearGross margin of 79.5%, non-GAAP gross margin of 79.9%Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 millionU.S. installed base of 1,465 accounts as of December 31, 2025U.S. Plaque installed base of 489 accounts as of December 31, 2025Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives
VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at
MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking GAMEFILM Registry. Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will now extend to include former players from the National Basketball Association (NBA) and the National Hockey League (NHL), broadening Heartflow's initiative to protect the heart health of professional athletes across major sports. Retired NBA star Muggsy Bogues was one of the first former professional basketball players to join the GAMEFILM